Overview
CLYM market data
Price History
CLYM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.36 – $14.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $720.4 · P/B 1.70.
Company news
8-K filing — Climb Bio, Inc. (CLYM)SEC EDGAR · Jul 1, 2026, 8:15 PM
Climb Bio Launches $100M At-The-Market Common Stock Offering Via JefferiesBenzinga · Jun 12, 2026, 8:30 PM
Why Is Climb Bio Stock Gaining Friday?Benzinga · Jun 12, 2026, 2:20 PM
Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price TargetBenzinga · Jun 12, 2026, 2:00 PM
BTIG Maintains Buy on Climb Bio, Raises Price Target to $20Benzinga · Jun 11, 2026, 3:41 PM
Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune ThrombocytopeniaBenzinga · Jun 11, 2026, 11:07 AM
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On MondayBenzinga · Jun 8, 2026, 2:35 PM
Guggenheim Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $35Benzinga · Jun 8, 2026, 2:25 PM
Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight SeriesBenzinga · Jun 5, 2026, 11:10 AM
Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026Benzinga · Jun 5, 2026, 11:10 AM